Research Collaboration and License Agreements - Additional Information (Details) - USD ($) $ in Thousands		12 Months Ended				15 Months Ended	24 Months Ended
	Mar. 16, 2022	Dec. 31, 2023	Mar. 31, 2022	Dec. 31, 2021	Dec. 31, 2015	Mar. 31, 2022	Mar. 31, 2024	Dec. 31, 2022
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Amount of additional fund received for research activities						$ 20,000
Contract liabilities		$ 0						$ 366
Research Collaboration and License Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Related party contract asset		0						0
Contract liabilities		0						$ 400
Proof-Of-Concept Trial, CVM Research Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Milestone payment for potential achievement of certain clinical development events		10,000
Merck Amended Agreement | Proof-Of-Concept Trial, CVM Research Program
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Option exercise fee		$ 6,000
Merck Sharp & Dohme Corp
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Percent of stock owned by counterparty		16.00%
Merck Sharp & Dohme Corp | Research Collaboration and License Agreements
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Receivable from collaboration		$ 4,750
Merck Sharp & Dohme Corp | Merck Original Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Performance of R&D services period					5 years
Additional term				2 years	2 years
Amount of fund received for research activities					$ 75,000
Research collaboration and license agreements extension fee		20,000			$ 20,000
Merck Sharp & Dohme Corp | Merck Amended Agreement
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Additional term	2 years
Amount of fund received for research activities			$ 86,000
Research collaboration and license agreements extension fee		$ 20,000
Amount of additional fund received for research activities			$ 15,100
Remaining extension term		2 years
Remaining extension fee		$ 16,000
Required amount to expend		$ 35,000
Research and development performance obligation period		3 years
Remaining performance obligation		$ 119,000
Due from related party		$ 4,750
Merck Sharp & Dohme Corp | Merck Amended Agreement | Forecast
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reimbursable expense							$ 13,100